首页> 美国卫生研究院文献>Journal of Lipid Research >Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets
【2h】

Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets

机译:HBEC中鼻病毒复制过程中的宿主脂质组分析确定了潜在的治疗靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In patients with asthma or chronic obstructive pulmonary disease, rhinovirus (RV) infections can provoke acute worsening of disease, and limited treatment options exist. Viral replication in the host cell induces significant remodeling of intracellular membranes, but few studies have explored this mechanistically or as a therapeutic opportunity. We performed unbiased lipidomic analysis on human bronchial epithelial cells infected over a 6 h period with the RV-A1b strain of RV to determine changes in 493 distinct lipid species. Through pathway and network analysis, we identified temporal changes in the apparent activities of a number of lipid metabolizing and signaling enzymes. In particular, analysis highlighted FA synthesis and ceramide metabolism as potential anti-rhinoviral targets. To validate the importance of these enzymes in viral replication, we explored the effects of commercially available enzyme inhibitors upon RV-A1b infection and replication. Ceranib-1, D609, and C75 were the most potent inhibitors, which confirmed that FAS and ceramidase are potential inhibitory targets in rhinoviral infections. More broadly, this study demonstrates the potential of lipidomics and pathway analysis to identify novel targets to treat human disorders.
机译:在患有哮喘或慢性阻塞性肺疾病的患者中,鼻病毒(RV)感染可引起疾病的急性恶化,并且存在有限的治疗选择。宿主细胞中的病毒复制诱导细胞内膜的显着重塑,但很少有研究以机械方式或作为治疗机会来探索这一点。我们对在RV的RV-A1b株感染6小时后的人支气管上皮细胞进行了公正的脂质组学分析,以确定493种不同脂质种类的变化。通过途径和网络分析,我们确定了许多脂质代谢和信号转导酶的表观活性的时间变化。分析尤其强调了FA合成和神经酰胺代谢是潜在的抗鼻病毒靶标。为了验证这些酶在病毒复制中的重要性,我们探讨了市售酶抑制剂对RV-A1b感染和复制的影响。 Ceranib-1,D609和C75是最有效的抑制剂,这证实了FAS和​​神经酰胺酶是鼻病毒感染的潜在抑制目标。更广泛地说,这项研究证明了脂质组学和途径分析潜在的潜力,可以确定治疗人类疾病的新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号